Donate For Public and Patients Store Search

S014 - Chronic Pruritus: Bedside to Bench Perspectives

Friday, March 1; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Evaluate the patient who has chronic itch.
  • Formulate a treatment plan for the patient who suffers from chronic itch

Description

Chronic pruritus has considerable impact on patient quality of life. Successful treatment has been a challenge that is beginning to be met as a result of advances in understanding the underlying physiology and pathophysiology of itch accompanied by targeted therapeutic approaches. This session is geared toward the practicing physician. It addresses advances in our understanding of itch, workup of the itchy patient and cutting edge approaches to treatment. This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org.

Disclosures

  • Chen, Suephy C., MD: BioPharmX – O(IP); Dermecular Therapeutics – O(IP); Leo Pharma Inc. – A(H); Phoenix Tissue Repair – O(IP); Trevi Therapeutics – O(IP); Unilever – O(IP);
  • Evers, Andrea: no financial relationships exist with commercial interests.
  • Kim, Brian S, MD: AbbVie – C(Fees); Cara Therapeutics – A(H); Incyte Corporation – A(H); Kiniksa Pharmaceuticals, Ltd. – A(H); Menlo Therapeutics – C(Fees); Nuogen Pharma – F(ST); Pfizer Inc. – C(H); Regeneron – A(H);
  • Lerner, Ethan A., MD, PhD: Dermira – A(Fees); Lerner Medical Devices, Inc. – F(NC); Menlo Therapeutics – A(Fees); Merck & Co., Inc – C(Fees); Sienna Biopharmaceuticals – A(Fees); Toray Industries, Inc. – C(Fees);
  • Stander, Sonja, MD: Almirall – C(H); Bayer – C(H); Beiersdorf, Inc. – C(H); Bellus Health – C(H); Bionorica – C(H); Cara Therapeutics – C(H); Celgene – C(H); Dermasence – I(Grants/Research Funding); DS Biopharma – C(H); Galderma Laboratories, LP – C(H); Galderma Research & Development, LLC – C(H); Galderma USA – I(Grants/Research Funding); Kiniksa Pharmaceuticals, Ltd. – C(H), I(Grants/Research Funding); Kneipp – C(H); Menlo Therapeutics – I(Grants/Research Funding); Menlo Therapeutics Inc. – C(H); Merz Pharmaceuticals, LLC – C(H); Novartis – C(H), I(Grants/Research Funding); Perrigo Company – C(H); Sanofi – I(Grants/Research Funding); Sienna Biopharmaceuticals – C(H); Trevi Therapeutics – C(H), I(Grants/Research Funding); Vanda Pharmaceuticals Inc. – I(H);
  • Xu, Steve, MD: Aclaris Therapeutics Inc. – C(Fees); LEO Pharma, US – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding);
  • Yosipovitch, Gil, MD: Galderma Laboratories, L.P. – A(H); Kiniksa Pharmaceuticals, Ltd. – I(Grants/Research Funding); Menlo Therapeutics – A(H), I(Grants/Research Funding); Novartis – C(H); OPKO Health, Inc – C(H); Pfizer Inc. – A(H), I(Grants/Research Funding); Sanofi/Regeneron – A(H); Sienna Biopharmaceuticals – A(H); Sun Pharmaceutical Industries Ltd. – I(Grants/Research Funding); Trevi Therapeutics – A(H);
Schedule
Friday, March 1
1:00 PM
Dr. Lerner / Introduction
1:05 PM
Dr. Stander / Chronic itch
1:35 PM
Dr. Chen / Pruritus in children
2:05 PM
Dr. Kim / Itchy conversations between the neural and immune systems
2:35 PM
Dr. Xu / Quantifying itch
2:50 PM
Dr. Evers / Placebo effects in itch
3:20 PM
Dr. Yosipovitch / Itchy tails
3:50 PM
All faculty / Q&A
Event Details
  • Date
    Friday, March 1
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 144A
  • CME Credits
    3.00
  • Type
    MOC
Directors/Co-Directors
  • Ethan A. Lerner, MD, PhD, FAAD
Speakers
  • Andrea Evers
  • Brian S Kim, MD, FAAD
  • Gil Yosipovitch, MD
  • Sonja Stander, MD - Handout
  • Steve Xu, MD, FAAD
  • Suephy C. Chen, MD, FAAD - Handout